{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:26:56Z","timestamp":1774596416126,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023181","name":"Agencja Bada\u0144 Medycznych","doi-asserted-by":"publisher","award":["2019\/ABM\/01\/00009"],"award-info":[{"award-number":["2019\/ABM\/01\/00009"]}],"id":[{"id":"10.13039\/501100023181","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ijcard.2024.132897","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:38:17Z","timestamp":1733531897000},"page":"132897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Prolonged antithrombotic treatment after de-escalation of dual antiplatelet therapy in patients after acute coronary syndrome - which strategy should be applied? The ELECTRA-SIRIO 2 investigators standpoint"],"prefix":"10.1016","volume":"421","author":[{"given":"Jacek","family":"Kubica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Adamski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Ostrowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldona","family":"Kubica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Gajda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolita","family":"Badariene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Budaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Fabiszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Gurbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"G\u0105sior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Hajdukiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Hudzik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi\u0142osz","family":"Jaguszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Janion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Kern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Poskrobko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Klecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wac\u0142aw","family":"Kochman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiktor","family":"Kuliczkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Przemys\u0142aw","family":"Magielski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Niezgoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Pietrzykowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Skonieczny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"di Somma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Szyma\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkadiusz","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Skowronek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta M.","family":"Siller-Matula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udaya","family":"Tantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia M.","family":"Umi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliano P.","family":"Navarese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijcard.2024.132897_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132897_bb0010","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5603\/CJ.a2022.0026","article-title":"Pre-hospital treatment of patients with acute coronary syndrome: recommendations for medical emergency teams. Expert position update 2022","volume":"29","author":"Kubica","year":"2022","journal-title":"Cardiol. J."},{"issue":"38","key":"10.1016\/j.ijcard.2024.132897_bb0015","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"Ibanez B; ESC scientific document group. 2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"issue":"36","key":"10.1016\/j.ijcard.2024.132897_bb0020","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ijcard.2024.132897_bb0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5603\/CJ.a2020.0132","article-title":"Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines","volume":"27","author":"Kubica","year":"2020","journal-title":"Cardiol. J."},{"issue":"13","key":"10.1016\/j.ijcard.2024.132897_bb0030","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/14656566.2018.1510487","article-title":"Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations","volume":"19","author":"Adamski","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"issue":"21","key":"10.1016\/j.ijcard.2024.132897_bb0035","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132897_bb0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5603\/CJ.a2021.0118","article-title":"Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: rationale and design of the ELECTRA-SIRIO 2 trial","volume":"29","author":"Kubica","year":"2022","journal-title":"Cardiol. J."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132897_bb0045","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5603\/CJ.a2021.0056","article-title":"A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study","volume":"28","author":"Kubica","year":"2021","journal-title":"Cardiol. J."},{"issue":"10","key":"10.1016\/j.ijcard.2024.132897_bb0050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.33963\/KP.a2022.0198","article-title":"Summary of the European Society of Cardiology guidelines on dual antiplatelet therapy in patients after percutaneous coronary interventions","volume":"80","author":"Hudzik","year":"2022","journal-title":"Kardiol. Pol."},{"issue":"11","key":"10.1016\/j.ijcard.2024.132897_bb0055","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijcard.2024.132897_bb0060","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"7578","key":"10.1016\/j.ijcard.2024.132897_bb0065","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/bmj.38985.646481.55","article-title":"Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)","volume":"333","author":"Fox","year":"2006","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ijcard.2024.132897_bb0070","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jacc.2005.08.039","article-title":"Plasma levels of soluble tumor necrosis factor receptor type I during the acute phase following complicated myocardial infarction predicts survival in high-risk patients","volume":"46","author":"Ueland","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132897_bb0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/01.CIR.93.2.229","article-title":"Platelet function in acute myocardial infarction treated with direct angioplasty","volume":"93","author":"Gawaz","year":"1996","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132897_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/clc.2","article-title":"Association of platelet-monocyte aggregates with platelet activation, systemic inflammation, and myocardial injury in patients in patients with non-st elevation acute coronary syndromes","volume":"30","author":"Zhang","year":"2007","journal-title":"Clin. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132897_bb0085","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4244\/EIJ-D-17-00092","article-title":"Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry","volume":"13","author":"De Luca","year":"2017","journal-title":"EuroIntervention"},{"issue":"17","key":"10.1016\/j.ijcard.2024.132897_bb0090","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1080\/14656566.2016.1241234","article-title":"New directions for pharmacotherapy in the treatment of acute coronary syndrome","volume":"17","author":"Adamski","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"15","key":"10.1016\/j.ijcard.2024.132897_bb0095","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehac829","article-title":"Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis","volume":"44","author":"Kang","year":"2023","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.ijcard.2024.132897_bb0100","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3390\/jcm9092983","article-title":"De-escalation of antiplatelet treatment in patients with myocardial infarction who underwent percutaneous coronary intervention: A review of the current literature","volume":"9","author":"Claassens","year":"2020","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.ijcard.2024.132897_bb0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5603\/MRJ.a2023.0014","article-title":"Antiplatelet therapy in elderly patients after acute coronary syndrome","volume":"1","author":"Di Somma","year":"2023","journal-title":"Med Res J."},{"issue":"25","key":"10.1016\/j.ijcard.2024.132897_bb0110","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: A consensus document from the academic research consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.132897_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-023-00901-2","article-title":"De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a consensus statement from an international expert panel on coronary thrombosis","author":"Gorog","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"41","key":"10.1016\/j.ijcard.2024.132897_bb0120","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur. Heart J."},{"issue":"10104","key":"10.1016\/j.ijcard.2024.132897_bb0125","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"issue":"10308","key":"10.1016\/j.ijcard.2024.132897_bb0130","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(21)01445-8","article-title":"Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial","volume":"398","author":"Kim","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132897_bb0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11239-011-0611-8","article-title":"Genetic determinants of platelet response to clopidogrel","volume":"32","author":"Kubica","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"issue":"9749","key":"10.1016\/j.ijcard.2024.132897_bb0140","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ijcard.2024.132897_bb0145","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"issue":"9749","key":"10.1016\/j.ijcard.2024.132897_bb0150","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2024.132897_bb0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fcvm.2019.00176","article-title":"Stratified approaches to antiplatelet therapies based on platelet reactivity testing","volume":"6","author":"Ostrowska","year":"2019","journal-title":"Front Cardiovasc Med."},{"issue":"17","key":"10.1016\/j.ijcard.2024.132897_bb0160","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for Oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijcard.2024.132897_bb0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: world heart federation expert consensus statement on antiplatelet therapy in east Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"10257","key":"10.1016\/j.ijcard.2024.132897_bb0170","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(20)31791-8","article-title":"Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial","volume":"396","author":"Kim","year":"2020","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.ijcard.2024.132897_bb0175","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ijcard.2024.132897_bb0180","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Jang Y; TICO Investigators. Effect of Ticagrelor monotherapy vs Ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.ijcard.2024.132897_bb0185","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ijcard.2024.132897_bb0190","doi-asserted-by":"crossref","first-page":"855","DOI":"10.5603\/CJ.a2021.0101","article-title":"P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial","volume":"28","author":"Roh","year":"2021","journal-title":"Cardiol. J."},{"issue":"24","key":"10.1016\/j.ijcard.2024.132897_bb0195","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"10439","key":"10.1016\/j.ijcard.2024.132897_bb0200","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijcard.2024.132897_bb0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ehjcvp\/pvz004","article-title":"Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study","volume":"5","author":"Kubica","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"3","key":"10.1016\/j.ijcard.2024.132897_bb0210","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/ehjcvp\/pvx032","article-title":"Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early after myocardial infarction (ELECTRA) pilot study","volume":"4","author":"Kubica","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"2","key":"10.1016\/j.ijcard.2024.132897_bb0215","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/03007995.2020.1854207","article-title":"Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease","volume":"37","author":"Adamski","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132897_bb0220","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5603\/MRJ.a2020.0043","volume":"5","author":"Kubica","year":"2020","journal-title":"Med Res J."},{"issue":"23","key":"10.1016\/j.ijcard.2024.132897_bb0225","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"DAPT study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.ijcard.2024.132897_bb0230","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"19","key":"10.1016\/j.ijcard.2024.132897_bb0235","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"PEGASUS-TIMI 54 steering committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.ijcard.2024.132897_bb0240","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","article-title":"Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54","volume":"37","author":"Bonaca","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.132897_bb0245","author":"Brilique product information"},{"issue":"4","key":"10.1016\/j.ijcard.2024.132897_bb0250","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ehjcvp\/pvz020","article-title":"Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54","volume":"5","author":"Dellborg","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"14","key":"10.1016\/j.ijcard.2024.132897_bb0255","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.ijcard.2024.132897_bb0260","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/CIRCULATIONAHA.118.033580","article-title":"Combination antiplatelet and Oral anticoagulant therapy in patients with coronary and peripheral artery disease","volume":"139","author":"Gurbel","year":"2019","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.ijcard.2024.132897_bb0265","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1093\/eurheartj\/ehac402","article-title":"Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54","volume":"43","author":"Bonaca","year":"2022","journal-title":"Eur. Heart J."},{"issue":"14","key":"10.1016\/j.ijcard.2024.132897_bb0270","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"Siontis GCM; ESC scientific document group. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.ijcard.2024.132897_bb0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5603\/MRJ.a2023.0011","article-title":"Bentracimab \u2014 a breakthrough for patients treated with antiplatelet agents?","volume":"1","author":"Adamski","year":"2023","journal-title":"Med Res J."},{"key":"10.1016\/j.ijcard.2024.132897_bb0280","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2021.10.138","article-title":"Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the START-ANTIPLATELET registry","volume":"345","author":"Cesaro","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132897_bb0285","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40256-022-00554-5","article-title":"Antithrombotic strategy in secondary prevention for high-risk patients with previous acute coronary syndrome: overlap between the PEGASUS eligibility and the COMPASS eligibility in a large multicenter registry","volume":"23","author":"Millesimo","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"2","key":"10.1016\/j.ijcard.2024.132897_bb0290","first-page":"141","article-title":"Antiplatelets in acute coronary syndrome in Poland - from guidelines to clinical practice","volume":"17","author":"Tubek","year":"2021","journal-title":"Postepy Kardiol Interwencyjnej."},{"issue":"31","key":"10.1016\/j.ijcard.2024.132897_bb0295","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/eurheartj\/ehab277","article-title":"Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy","volume":"42","author":"Crea","year":"2021","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.ijcard.2024.132897_bb0300","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jama.2020.26020","article-title":"Ticagrelor vs Clopidogrel for patients with acute coronary syndrome undergoing percutaneous intervention","volume":"325","author":"Kim","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.ijcard.2024.132897_bb0305","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/eurheartj\/ehv573","article-title":"Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma","volume":"37","author":"Gurbel","year":"2016","journal-title":"Eur. Heart J."},{"issue":"1\u20132","key":"10.1016\/j.ijcard.2024.132897_bb0310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000371392","article-title":"Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction","volume":"95","author":"Kubica","year":"2015","journal-title":"Pharmacology"},{"issue":"1","key":"10.1016\/j.ijcard.2024.132897_bb0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5603\/KP.a2015.0117","article-title":"Prediction of high risk of non-adherence to antiplatelet treatment","volume":"74","author":"Kubica","year":"2016","journal-title":"Kardiol. Pol."},{"issue":"8","key":"10.1016\/j.ijcard.2024.132897_bb0320","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1080\/03007995.2016.1182901","article-title":"Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials","volume":"32","author":"Kubica","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.ijcard.2024.132897_bb0325","doi-asserted-by":"crossref","first-page":"582","DOI":"10.5603\/CJ.a2020.0005","article-title":"The impact of readiness to discharge from hospital on adherence to treatment in patients after myocardial infarction","volume":"29","author":"Kosobucka","year":"2022","journal-title":"Cardiol. J."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132897_bb0330","doi-asserted-by":"crossref","first-page":"12028","DOI":"10.1038\/s41598-020-68915-1","article-title":"Medication adherence and its determinants in patients after myocardial infarction","volume":"10","author":"Pietrzykowski","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ijcard.2024.132897_bb0335","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5603\/FC.2020.0003","article-title":"Rationale for motivational interventions as pivotal element of multilevel educational and motivational project (MEDMOTION)","volume":"15","author":"Kubica","year":"2020","journal-title":"Folia Cardiol."},{"key":"10.1016\/j.ijcard.2024.132897_bb0340","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/PPA.S150435","article-title":"Adherence to treatment assessed with the adherence in chronic diseases scale in patients after myocardial infarction","volume":"12","author":"Kosobucka","year":"2018","journal-title":"Patient Prefer. Adherence"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324015195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527324015195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:17:49Z","timestamp":1738408669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527324015195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":68,"alternative-id":["S0167527324015195"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132897","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged antithrombotic treatment after de-escalation of dual antiplatelet therapy in patients after acute coronary syndrome - which strategy should be applied? The ELECTRA-SIRIO 2 investigators standpoint","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.132897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"132897"}}